LEGAL PROCEEDINGS AND OTHER MATTERS (Details) (USD $)	6 Months Ended	1 Months Ended		6 Months Ended		9 Months Ended	3 Months Ended	12 Months Ended	1 Months Ended		3 Months Ended
	Jun. 30, 2011 AMRIX Patent litigation	Jul. 31, 2010 Patent litigation PROVIGIL	Mar. 31, 2003 Patent litigation PROVIGIL	Jun. 30, 2011 Patent litigation PROVIGIL	Jun. 30, 2011 Patent litigation NUVIGIL	Aug. 31, 2010 Patent litigation NUVIGIL	Sep. 30, 2007 Patent litigation DURASOLV	Dec. 31, 2007 Patent litigation DURASOLV	Feb. 28, 2009 U.S. Attorney's Office and Related Matters	Sep. 30, 2008 U.S. Attorney's Office and Related Matters	Dec. 31, 2008 U.S. Attorney's Office and Related Matters	Jun. 30, 2011 Other Matters	Jun. 30, 2011 Other Commitments
Legal proceedings and other matters
Number of companies against which patent infringement lawsuit is filed			4			7
Number of companies who were the first to file ANDAs with Paragraph IV certifications			4
Period of marketing exclusivity provided by the provisions of the Federal Food, Drug and Cosmetic Act (in days)			180
Number of companies affected by pharmaceutical sector inquiries conducted by the European Commission				100
Number of purported stockholders of the company who filed derivative suits		2
Number of lawsuits filed by purported stockholders of the company		2
Period of pediatric extension included in expiration period of the '516 Patent, the '346 Patent, and the '570 Patent (in months)					6
Stay period of any FDA approval of the applicable ANDA, assuming no earlier district court judgment in favor of the ANDA holder (in months)					30
Strengths of generic version of AMRIX (in mg)	15 mg and 30 mg
Period prior to expiration of the Eurand Patent when Impax's license becomes effective (in years)	1
Payment made under the Settlement Agreement with the United States Government											$ 375,000,000
Interest paid under the Settlement Agreement											11,300,000
Number of misdemeanor violations of the U.S. Food, Drug and Cosmetic Act pled guilty by the entity											1
Additional payment related to misdemeanor violation of the U.S. Food, Drug and Cosmetic Act											50,000,000
Period of Corporate Integrity Agreement with the OIG (in years)										5
Number of states with which State Settlement and Release Agreement is entered into by the entity										50
Payment made under the Connecticut Assurance										6,150,000
Payment made under the Massachusetts Settlement Agreement										700,000
Number of health and welfare trust funds on behalf of which additional putative class action complaint filed against the entity									2
Number of U.S. patents for which the examiner rejected the claims							2
Number of U.S. patents for which notices of appeal is filed to the board of patent appeals of the PTO's decisions								1
Number of putative class actions filed against the board and/or the entity												3
Potential milestone, option exercise payments and other contingency payments due under current contractual agreements													3,400,000,000
Contingent consideration													236,700,000
Fees contingent on closing of acquisition, not accrued													$ 29,500,000